The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Zai Lab’s delta-like ligand 3 (DLL3) antibody-drug conjugate (ADC), ZL-1310, for small cell lung cancer (SCLC).
UK Dedicated Servers Strengthens Partnership with Corero as First EMEA Adopter of New Adaptive NTD3400 DDoS Solution. MARLBOROUGH, Mass., Jan. /PRNewswire/ — Corero Net ...
Bybit, the world's second-largest cryptocurrency exchange by trading volume, officially marks the 3rd anniversary of its P2P ...
Zai Lab Limited (ZLAB) announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation or ODD to ZL-1310, a ...
The Conference on Jewish Material Claims Against Germany (Claims Conference) today released the first-ever, eight-country Index on Holocaust Knowledge and Awareness, exposing a global trend in fading ...
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan ...
Amado, M.D., President, Head of Global Research and Development at Zai Lab. “Building on the promising findings from our ongoing clinical trials for ZL-1310, this new collaboration demonstrates our ...
“Building on the promising findings from our ongoing clinical trials for ZL-1310, this new collaboration demonstrates our continued focus on developing cancer therapies with ADC drugs and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback